Background: Current diagnosis and staging of neuroendocrine tumors (NETs) are significantly improved by the introduction of the chromogranin A (CgA) assay in plasma or serum as a tumor marker, and by the use of somatostatin receptor scintigraphy (SRS) for tumor localization. However, the clinical role of CgA assay compared with SRS in the management of NETs has not been well elucidated.
Introduction
Neuroendocrine tumors (NETs) represent a heterogeneous group of neoplastic entities derived from cell populations of the diffuse neuroendocrine system; they encompass aggressive tumors such as neuroendocrine small-cell cancer, low-growing tumors such as carcinoid and tumors with intermediate aggressiveness such as malignant carcinoid [1, 2] . They are usually divided into functioning or non-functioning tumors according to their ability to produce, or not, hormones and biologically active substances responsible for clinical syndromes. Although these tumors often have a good prognosis, they are generally diagnosed late because of their versatile presentation. Current diagnosis and staging of NETs are significantly improved by the introduction of the chromogranin A (CgA) assay in plasma or serum, as a tumor marker [3] [4] [5] [6] , and by the use of somatostatin receptor scintigraphy (SRS) for tumor localization [7] [8] [9] [10] [11] . Human CgA is a glycoprotein belonging to the family of chromogranins, also known as secretogranins, which is present in the secretory granules storing peptide hormones and catecholamine throughout the neuroendocrine system. Elevated plasma CgA levels have been found in a variety (80-100%) of functional and non-functional NETs and the circulating CgA levels also reflect the tumor extent [12, 13] .
SRS using indium 111-DTPA-octreotide ( 111 In-pentetreotide) is widely used to localize NET since octreotide is able to bind to somatostatin receptor subtypes 2 and 5, and almost all (80%) NETs contain the somatostatin receptor subtype 2 [7, 14, 15] .
In a previous study, Kalkner et al. [16] found that positive 111 Inpentetreotide scintigraphy correlates with elevated levels of plasma CgA in patients with carcinoid tumors. However, the role of CgA assay compared with SRS has not been well elucidated. CgA production seems to depend on tumor type or tumor differentiation and the sensitivity of CgA assay as a tumor marker may be low in moderately or poorly differentiated neuroendocrine carcinomas [13] . On the other hand, the sensitivity of 111 In-pentetreotide scintigraphy may be of limited value in tumors <0.5 cm and in tumors lacking somatostatin receptor subtype 2 and 5 expression [14] . The aim of our study was to investigate the impact of SRS versus plasma CgA assay in patients with different types of NETs histologically diagnosed according to the new World Health Organization (WHO) clinicopathological formulation. We specifically compared the results of SRS and those of plasma CgA with regard to tumor staging, tumor response evaluation and follow-up.
Patients and methods

Patients
Sixty-three consecutive patients (32 men and 31 women, aged between 18 and 76 years) with a histological diagnosis of NETs underwent plasma CgA analysis and SRS for tumor staging (23 cases), evaluation of tumor response to chemotherapy and/or somatostatin analogs (18 cases) and evaluation of tumor recurrence on follow-up (22 cases). All patients gave informed consent to participation in the study. According to the WHO pathological formulation, the histological diagnosis included 21 well-differentiated neuroendocrine tumors (WDNETs: 18 gastroenteropancreatic tumors and three lung NETs), 22 welldifferentiated neuroendocrine carcinomas (WDNECs: 17 gastroenteropancreatic carcinomas, two lung neuroendocrine carcinomas and three neuroendocrine carcinomas of unknown origin), and 20 poorly differentiated neuroendocrine carcinomas (PDNECs: 14 extra-pulmonary small-cell carcinomas and six Merkel cell carcinomas). Patients with small-cell lung carcinoma, in whom spiral computed tomography (CT) is generally used as sensitive diagnostic procedure, were excluded from the study.
With regard to disease extent, the disease was defined as 'limited disease' (a tumor <2.5 cm or a tumor >2.5 cm without lymph-node metastases), 'locally advanced disease' (a tumor with lymph-node metastases) and 'metastatic disease'. Among the 63 patients investigated, only five (8%) were syndromic.
Immunoassay
The quantitative determination of CgA was performed in plasma using an enzyme immunoassay (DAKO Chromogranin A ELISA Kit; DAKO A/S Produktionsvej 42, DK-2600 Glostrup, Denmark). It is a simplified double antibody sandwich assay where samples and peroxidase-conjugated antibody to CgA are incubated simultaneously in microwells coated with antibody to CgA. After a washing step, the chromogenic substrate is added. Color development results from the oxidation of the substrate through an enzyme-catalyzed reaction. The assay uses rabbit antibodies to a 23 kDa C-terminal fragment of human CgA. CgA concentrations determined with the kit are given as U/l.
Total coefficients of variation (within and between assay) are 7.3% for mean levels of 30.5 U/l (n = 36), 8.6% for mean levels of 195.4 U/l (n = 30) and 5.8% for mean levels of 364.4 U/l (n = 30). In our laboratory, the normal CgA values obtained in healthy subjects (58 men aged 20-78 years and 57 women aged 20-75 years) ranged between 0 and 33.39 U/l (mean value ± standard deviation = 10.41 ± 7.66 U/l) with a cut-off value fixed at 34 U/l.
Somatostatin receptor scintigraphy
SRS was performed with 111
In-pentetreotide, a [ 111 In-DTPA-D-Phe-] conjugate of octreotide, a somatostatin analog, which binds to somatostatin receptor subtypes 2 and 5 (OctreoScan; Mallinckrodt Medical, Petten, The Netherlands). Planar or whole-body (WB) images, as well as single photon emission computed tomography (SPECT) of chest and abdomen were performed in all patients 4-6 h and 24 h after intravenous (i.v.) injection of 200-220 MBq of 111 In-pentetreotide (seldom continued for 48-72 h), using a rectangular large field of view gamma camera (Sophicamera DSX, Sopha; BUC, France). Planar images were acquired for 15-20 min/image, using a 256 × 256 word matrix; WB images, anterior and posterior, were acquired into a 2048 × 512 word matrix with a speed of 8 cm/min. All SPECT studies were performed using a 128 × 128 matrix, 64 projections with a rotation of 360° and 44-55 s acquisition time per projection, and SPECT row data were prefiltered using a Butterworth filter (order 8 and cut-off 0.15). The data were then reconstructed by a maximum activity projection algorithm using a ramp filter without attenuation correction.
Data interpretation
All patients with plasma CgA values >34 U/l were considered positive for neuroendocrine disease. Plasma CgA assays were obtained within 1-4 weeks of scintigraphy in all cases.
SRS was interpreted independently of the result of any prior investigation. To define the tumor as visualized during SRS, a simple yes-or-no system was used. Any focal activity higher than the surrounding background activity was considered a positive result if it was present on the images of both early 4-6 h and delayed 24-48 h studies.
SRS and CgA results were rated true-positive (TP) or true-negative (TN) based on the final data of surgery (n = 39) and/or of other diagnostic procedures such as spiral CT, magnetic resonance, ultrasonography and endoscopy (n = 24).
Results
Clinical data, SRS results and plasma CgA values of all 63 patients are summarized in Table 1 . At initial diagnosis (before SRS and plasma CgA investigations), 21 (33%) patients had limited disease, eight (13%) locally advanced disease and 34 (54%) metastatic disease. Fourteen of 21 patients with limited disease, and two of eight patients with locally advanced disease at initial diagnosis, were disease-free based on the final clinical data.
Of the 63 patients examined, 37 (59%) had scintigraphic lesions and 27 (43%) had plasma CgA levels above the normal limit (>34 U/l).
Concordance between SRS and CgA results
For all patients, the concordance between SRS and CgA results was 75%; 24 patients had positive scan findings and elevated CgA levels, and 23 had negative scan findings and CgA levels in the normal range ( 
Overall results for SRS and CgA assay based on final clinical data
We found one false-positive and 11 false-negative SRS results based on the final clinical data, as well as one false-positive and 21 false-negative CgA analyses (Table 3 ). The overall sensitivity (TP/TP + FN) of SRS and CgA was 77% and 55%, respectively; the specificity (TN/TN + FP) of both SRS and CgA was 94%. With regard to the histological classification, SRS sensitivity was 100% for WDNETs, 84% for WDNECs and 50% for PDNECs, whereas CgA sensitivity was 58% for WDNETs, 68% for WDNECs and 37% for PDNECs.
With regard to disease extent, SRS sensitivity was 100% for limited disease and 72% for advanced disease (locally advanced disease and metastatic disease); CgA sensitivity was 43% for limited disease and 57% for advanced disease. Figure 1 . A man aged 48 years at post-surgical staging for carcinoid tumor in the blind gut. Chromogranin A levels were within the normal range (13 U/l). Conversely, somatostatin receptor scintigraphy showed a focal activity in the abdomen (arrow), on early (A) and delayed (B) planar images. Threedimensional single photon emission computed tomography imaging (C, D) was useful in localizing the tumor site, which was a lymph-node metastasis on surgical exploration, not seen by other imaging procedures.
On the whole, SRS accuracy (TP + TN/TP + TN + FP + FN) was 81% and CgA accuracy was 65%. SRS provided additional detection sites compared with conventional imaging in only one case.
Discussion
In this study, we have investigated the clinical role of SRS and circulating CgA in the management of patients with NETs with respect to stage and type of neoplasm according to the revised WHO clinicopathological classification [1, 2, 17] .
We found that positive SRS correlated with elevated levels of plasma CgA, as reported by Kalkner et al. [16] ; however, SRS proved to be more sensitive than CgA with equivalent specificity (Figure 1) .
In previous reports, the specificity of SRS (expressed on a per patient basis) for NETs of the gastroenteropancreatic tract was 81% [18] , and the specificity of circulating CgA ranged between 68% and 95% depending on the upper threshold of the normal range [19, 20] . The sensitivity of SRS in any NETs varied between 78% and 100% [7, [15] [16] [17] [18] , whereas CgA levels depended on tumor type or disease extent and presence of functioning tumors [13, [19] [20] [21] .
Our results showed an overall specificity of both SRS and CgA for any NETs as high as 94%. We observed only one false-positive SRS result in a patient with limited disease, studied on follow-up (Table 1) . Similarly, only one false-positive CgA result was registered in a patient with WDNEC suffering from essential hypertension and arrhythmia (Table 1) . False-positive SRS results could be limited by having a thorough knowledge of other diseases or circumstances that can result in a false-positive response, as suggested by Gibril et al. [22] , and the accurate definition of the normal range of CgA values obtained in our healthy control group (n = 115) has increased the CgA specificity [19] .
In our study, the overall sensitivity of SRS (expressed on a per patient basis) was 77%. Moreover, SRS sensitivity was higher (100%) in the WDNET subgroup than in WDNECs (84%) and PDNECs (50%). The sensitivity of SRS was also higher (100%) in patients with limited disease than in patients with advanced disease (72%). This indicates that somatostatin receptor expression is more likely present in highly differentiated and low aggressive NETs.
Conversely, a low overall CgA sensitivity of 55% was found. It is interesting to note that in our patient series, almost all (58 of 63) NETs were non-functioning, and a low CgA sensitivity was observed both in patients with limited disease (43%) and in patients with advanced disease (57%). However, our data showed that the accuracy of CgA was more elevated in patients with low-growing NETs (76%) than in patients with intermediate aggressive neuroendocrine carcinomas (68%) or with poorly differentiated neuroendocrine carcinomas (50%), as reported in the literature [20, 23] .
Conclusions
In our NET series, which included many cases of highly aggressive (20 cases) and intermediate aggressive (22 cases) tumors, SRS showed a better sensitivity than CgA with equivalent high specificity. Our results confirm that tumor differentiation influences the sensitivity of SRS and CgA analysis. In addition, plasma CgA level is related to tumor secretory activity. Nevertheless, both SRS and CgA should be considered useful tools for the management of NET patients.
